Table 2.

Severe acute respiratory syndrome coronavirus 2 IgG antibody response and severe acute respiratory syndrome coronavirus 2 neutralizing capacity of patients on hemodialysis and healthy controls after vaccination with BNT162b2

Humoral ResponsesAll ParticipantsAge-Matched Participants
Healthy ControlsPatients on DialysisP ValueHealthy ControlsPatients on DialysisP Value
SARS-CoV-2 IgG antibody response
 Participants meeting threshold for positive response, N (%)
  After first vaccine43 (93)4 (18)<0.00112 (80)4 (20)<0.001
  After second vaccine46 (100)14 (82)<0.00115 (100)14 (82)<0.001
 Anti-S1 IgG index, median (IQR)
  After first vaccine9 (4–16)0.2 (0.1–0.7)<0.0016 (1–16)0.2 (0.1–0.7)<0.001
  After second vaccine81 (45–150)6 (1–11)<0.00174 (21–150)6 (1–11)<0.001
SARS-CoV-2 neutralizing capacity
 Participants meeting threshold for viral neutralization, N (%)
  After first vaccine43 (93)4 (18)<0.00112 (80)4 (20)<0.001
  After second vaccine46 (100)14 (82)<0.00115 (100)14 (82)<0.001
 Inhibition (%), median (IQR)
  After first vaccine65 (49–75)11 (3–24)<0.00162 (37–75)16 (7–24)<0.001
  After second vaccine98 (97–98)51 (32–86)<0.00198 (92–98)51 (32–86)<0.001
  • SARS-CoV-2, severe acute respiratory syndrome coronavirus 2; IQR, interquartile range.